Filter posts

Neglected Diseases: What if IP was the Cure?

The Lancet Global Health Journal recently published an article “The drug and vaccine landscape for …

South Africa National Policy on Intellectual Property: Inconsistent with Biotech Development Goals

BIO submitted comments this week to the government of South Africa on their proposed “Draft …

New Bill Calls for No WTO-Plus Benefits for Countries that Violate IP

A new Bill in the U.S. House of Representatives seeks to remove WTO-plus trade benefits …

India’s IP Policy: India’s Lead Biotech Innovator Expresses Concern

Kiran Mazumdar-Shaw, chairperson and managing director of India’s largest biotechnology company Biocon, expressed concern with …

BIO Joins Alliance for Fair Trade with India

BIO recently joined the Alliance for Fair Trade with India along with the U.S. Chamber …

MERS, Patents, and Material Transfer Agreements: What WHO Didn't Know

The outbreak of the Middle East Respiratory Syndrome (MERS-CoV), a SARS like virus has lead …

IP in Latin America: Growing Recognition of the Importance of IP to Innovation

The Inter-American Dialogue’s daily Latin America Advisor recently asked the question “How seriously do Latin …

Session Summary: What Every CEO Must Know About IP In Biotech

On Sunday, April 21st, 2013, I attended a standing room only session titled, “What Every …

Kirtsaeng v. John Wiley & Sons: No Good Deed Goes Unpunished

The Supreme Court handed Kirtsaeng a victory last week finding his importation and resale of …

Spotlight on India’s Emerging Biotech Sector

India’s biotechnology sector is a burgeoning one, with more than 325 companies and some with …